EUCTR2005-003351-12-GR进行中（未招募）不适用
THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF) - EMPHASIS-HF
Pfizer Hellas AE0 个研究点目标入组 2,584 人开始时间: 2006年7月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,584
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •1. Written informed consent obtained prior to the initiation of any study procedures
- •2. Male or female subjects, = 60 years of age at the time informed consent is obtained
- •3. Chronic systolic heart failure (HF) of either ischaemic or non-ischaemic aetiology:
- •a. Duration: at least 4 weeks
- •b. Left ventricular ejection fraction (LVEF): = 30% by echocardiography, contrast ventriculography, magnetic resonance imaging or nuclear imaging, based on local clinical practice. The most recent measurement within 6 months prior to randomisation must be used.
- •c. Functional Capacity: Currently NYHA II (in the investigator’s opinion)
- •d. Treatments (for ACE inhibitors, ARBs and b-blockers, optimal target or maximal tolerated dose unless contraindicated):
- •·Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs)
- •·ß-blocker
- •·Diuretic, if clinically indicated to reduce fluid retention
- •4. Serum potassium (K+) level = 5.0mmol/L within 24 hours prior to randomisation
- •5. Estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 within 24 hours prior to randomisation.
- •6. Randomisation must occur no later than 90 days from the date of admission for index cardiovascular (CV) hospitalisation. (If clinically stable, the subject may be randomised during this index cardiovascular (CV) hospitalisation.)
- •7. If the subject is a female of childbearing potential, she must:
- •a. Have a negative serum pregnancy within 72 hours prior to the first dose of study drug
- •b. Agree to use an adequate form of contraception (Abstinence will not be considered an acceptable form of contraception.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the trial:
- •1. Patients with severe chronic systolic heart failure, defined as patients who demonstrate symptoms usually at rest despite optimal medical therapy
- •2. Patients with a myocardial infarction complicated by left ventricular systolic dysfunction and clinical heart failure within 30 days prior to randomisation
- •3. Patients with stroke within 30 days prior to randomisation
- •4. Patients who have had cardiac surgery within 30 days prior to randomisation
- •5. Patients who have had percutaneous coronary intervention (PCI) within 30 days prior to randomisation
- •6. Patients, who in the opinion of the investigator, require treatment with eplerenone, spironolactone or potassium canrenoate
- •7. Patients with uncontrolled hypertension, defined as having a systolic blood pressure = 180 mmHg and/or a diastolic blood pressure = 110 mmHg
- •8. Patients with symptomatic hypotension or having a systolic blood pressure = 85 mmHg
- •9. Patients, who in the opinion of the investigator, require treatment with potassium-sparing diuretics or potassium supplements
- •10. History of hypersensitivity to eplerenone or spironolactone
- •11. Evidence of cardiogenic shock
- •12. Patients in whom the primary cause of heart failure is valve disease, pericardial disease or an obstructive or restrictive cardiomyopathy .
- •13. Intra-aortic balloon pump or other mechanical assist device
- •14. Patients awaiting cardiac transplantation
- •15. Serum potassium > 5.0 mmol/L within 24 hours prior to randomisation
- •16. Estimated glomerular filtration rate (eGFR) =30 ml/min/1.73m2 within 24 hours prior to randomisation.
- •17. Concomitant use of potent cytochrome p450 3A4 (CYP3A4) inhibitors, such as but not limited to:
- •a.Ketoconazole
- •b.Itraconazole
- •c.Nefazodone
- •d.Troleandomycin
- •e.Clarithromycin
- •f.Ritonavir
- •g.Nelfinavir
- •18. Concomitant use of cytochrome p450 3A4 (CYP3A4) inducers, such as but not limited to:
- •a. St. John’s Wort
- •b. Rifampin
- •c. Carbamazepine
- •d. Phenytoin
- •e. Phenobarbitol
- •19. Hemoglobin <10g/dL
- •20. Patients with preexisting significant hepatic disease (for example, known positive serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limits of normal
- •21. Patients status-post gastric bypass surgery, partial gastrectomy or other surgery of the gastrointestinal tract that may interfere with the absorption of eplerenone
研究者
相似试验
进行中（未招募）
1 期
THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF) - EMPHASIS-HFChronic systolic heart failureMedDRA version: 8.0 Level: LLT Classification code 10008908EUCTR2005-003351-12-GBPfizer Limited3,102
进行中（未招募）
不适用
THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALIZATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILUREChronic systolic heart failureMedDRA version: 14.1Level: PTClassification code 10007558Term: Cardiac failure chronicSystem Organ Class: 10007541 - Cardiac disordersEUCTR2005-003351-12-ITPFIZER3,102
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-BEPfizer Inc.2,715
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-PTaboratórios Pfizer, Lda2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-IEPfizer Limited2,584